2025 Telematics Report Reveals Industry Growing Pains Amid Rapid Tech Adoption
(NewsUSA)
- Commercial auto insurance and fleet safety are meeting the demands of modern-day risk management by analyzing telematics, but more work is needed to optimize this information and put it into action in the industry, according to results of a new report from SambaSafety, the leading provider of cloud-based driver risk management solutions.
Telematics is used by commercial insurers to capture driving patterns from telematics devices their fleet customer use, such as visibility into riskier driving such as speed, mileage, and braking— empowering insurers to collaborate with fleets on tailored coverage and proactive risk consulting strategies.
The 2025 SambaSafety Telematics Report: Uncovering Market Dynamics and Technology Trends, shows that telematics is front and center in the risk and safety ecosystem, according to SambaSafety CEO Matt Scheuing.
“The current state of commercial auto reflects an industry under strain, but also one on the edge of transformation, with telematics at the center,” said Matt Scheuing, CEO of SambaSafety. “When fleets and insurers connect through shared data and trust, we move closer to a market that prevents losses instead of reacting to them.
“At SambaSafety, we’re closing that gap for millions of drivers through our Risk Cloud, integrating telematics, court, DOT and claims data to deliver actionable insights and targeted training—through our newly enhanced driver app. With our SambaSafety Verified program, we’re also helping insurers identify and reward fleets that actively manage risk. Together, these advancements represent the next step in connecting our customers through shared data, smarter insights and measurable safety outcomes.”
The new report includes survey responses from industries including trucking & transportation, construction, energy, utilities, government, and healthcare. SambaSafety collected responses from 152 individuals from fleets, 180 insurance brokers and 70 insurance carriers, all based in North America, in June and July 2025.
Overall, 88% of fleets reported using telematics for safety reasons, and 95% considered driver training important.
However, the complexity of the data and technical challenges of integration were mentioned often as barriers to using telematics more widely in optimizing insurance.
Nearly two-thirds (66%) of fleets said that “interpreting or acting on the data” was a challenge, and 58% of fleet drivers said that linking drivers to their data remains an operational concern.
Telematics data is reshaping relationships between commercial fleets and insurers, but there is room for improvement in collaboration, according to the SambaSafety survey. Although 41% of fleets reported that use of telematics lowered their insurance premiums, 70% of fleets rarely interact with insurers around telematics, creating a gap in shared innovation and risk reduction. When insurers initiate telematics discussions, fleets report strong partnership in risk reduction—yet 79% of non-engaged fleets say that outreach never happens.
The 2025 SambaSafety Telematics Report: Uncovering Market Dynamics and Technology Trends is available for download. For more information and to access the report, visit sambasafety.com.
- A Michigan university unveils SOAR™, a new smartphone-based degree program that brings college within reach for busy adults — at half the cost.
- Over the next two decades, more than
- One in four students in the United States today is Hispanic. Yet, despite this growing presence, Latino families are still underrepresented in many states' public and private school choice programs. In most cases, we don’t even know by how much.
-
- Small cell lung cancer (SCLC) is among the most aggressive, deadliest forms of lung cancer, yet it’s still too often overlooked. For decades, treatment options were limited, offering little hope to those diagnosed with SCLC, until now.
Because of research, treatments like the recently FDA-approved Tarlatamab belong to a class of drugs called bispecific T-cell engagers (BiTEs), which harness the immune system to combat cancer. Another treatment, Lurbinectedin, slows or stops the growth of cancer cells in your body. There are also next-generation approaches, such as CAR T-cell therapy and antibody-drug conjugates, and many others, now in clinical trials. Clinical trials, once a last resort, are rapidly becoming a front door to tomorrow’s breakthroughs.
- Young children are naturally curious, and an innovative program from BrightPath Early Learning and Child Care puts this curiosity center stage. The BrightPath curriculum, BeeCurious, involves guided exploration and multiple forms of expression while offering preschoolers autonomy and choices and celebrating learning as a joyful experience.
- America’s story has been written by those bold enough to begin. The revolutionaries who founded a new nation, the farmer who moved west to claim and seed land, the inventor who built a new machine, and the newcomer who opened a small shop on Main Street were all pioneers. Each had no guarantee of success. Each carried the promise of progress.
- Do you ever notice a flutter in your chest? Feel unusually tired even after a good night’s sleep? Get winded from walking up the stairs when that never used to happen? These little signs might not feel like a big deal, but they could point to something more serious: atrial fibrillation, or AFib.
- Between deciding where to apply, visiting campuses, and completing financial aid forms, October can feel like crunch time for college-bound students, with